1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended September 30, 2022.
+Added: The table below reflects shares of Common Stock we repurchased under our share repurchase programs, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended March 31, 2023.
Refer to Part I, Item 2.
−Removed: "Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources" for further details of the share repurchase program.
−Removed: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Programs Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs
+Added: "Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources" for further details of the share repurchase programs.
+Added: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Programs Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs (b)
(in millions)
3 unchanged sentences
Total 933,833 (a)
−Removed: 1,494,017 (a)
−Removed: (a) The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.
+Added: (a) The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced programs relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.
+Added: (b) In January 2023, our board of directors authorized an additional share repurchase program to repurchase up to $3.0 billion of our Common Stock.
+Added: See Part I, Item 2.
+Added: "Liquidity and Capital Resources - Share Repurchase Programs " for further details.
Exhibit Number Description
−Removed: 10.1 Modification No.
−Removed: 02 to Base Agreement, dated as of August 2, 2022, by and between Regeneron Pharmaceuticals, Inc.
−Removed: (the "Registrant") and Advanced Technology International.
−Removed: 10.2* Modification No.
−Removed: 03 to Project Agreement, dated as of May 21, 2021, by and between the Registrant and Advanced Technology International.
−Removed: 10.3 Modification No.
−Removed: 04 to Project Agreement, dated as of July 12, 2021, by and between the Registrant and Advanced Technology International.
−Removed: 10.4* Modification No.
−Removed: 06 to Project Agreement, dated as of July 12, 2022, by and between the Registrant and Advanced Technology International.
−Removed: 10.5* Modification P00001 to Supply Agreement, dated as of March 9, 2021, by and between the Registrant and the U.S.
−Removed: Army Contracting Command, New Jersey.
−Removed: 10.6* Modification P00002 to Supply Agreement, dated as of June 17, 2021, by and between the Registrant and the U.S.
−Removed: Army Contracting Command, New Jersey.
−Removed: 10.7 Modification P00003 to Supply Agreement, dated as of July 8, 2021, by and between the Registrant and the U.S.
−Removed: Army Contracting Command, New Jersey.
−Removed: 10.8* Modification P00007 to Supply Agreement, dated as of July 29, 2022, by and between the Registrant and the U.S.
−Removed: Army Contracting Command, New Jersey.
+Added: First Amendment to the Regeneron Pharmaceuticals, Inc.
+Added: Cash Incentive Bonus Plan.
+Added: Third Amended and Restated Participation Agreement, dated as of March 27, 2023, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent, BA Leasing BSC, LLC, as lessor, and the rent assignees party thereto from time to time.
+Added: (Incorporated by reference from the Form 8-K for Regeneron Pharmaceuticals, Inc.
+Added: (the "Registrant"), filed March 29, 2023.)
+Added: Third Amended and Restated Lease and Remedies Agreement, dated as of March 27, 2023, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor.
+Added: (Incorporated by reference from the Form 8-K for the Registrant, filed March 29, 2023.)
+Added: Third Amended and Restated Guaranty, dated as of March 27, 2023, made by the Registrant, Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC, as guarantors.
+Added: (Incorporated by reference from the Form 8-K for the Registrant, filed March 29, 2023.)
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
3 unchanged sentences
101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"):
−Removed: (i) the Registrant's Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021;
−Removed: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2022 and 2021;
−Removed: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021;
−Removed: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021;
+Added: (i) the Registrant's Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022;
+Added: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2023 and 2022;
+Added: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2023 and 2022;
+Added: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022;
and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
−Removed: * Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K
+Added: † Indicates a management contract or compensatory plan or arrangement.
+Added: * Certain of the exhibits and/or schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5).
+Added: The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
REGENERON PHARMACEUTICALS, INC.
−Removed: November 3, 2022 By:
+Added: May 4, 2023 By:
/s/ Robert E.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.